Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 55
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03841565 | Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | ||
| NCT04351230 | T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer | ||
| NCT06238648 | Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy | ||
| NCT03688230 | Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer. | ||
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | ||
| NCT04660760 | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer | ||
| NCT02234180 | Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery | ||
| NCT04659044 | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | ||
| NCT02158520 | Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | ||
| NCT04042831 | Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations | ||
| NCT04756401 | Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma | ||
| NCT02037529 | Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer | ||
| NCT01532089 | Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations | ||
| NCT01867294 | Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab | ||
| NCT04626791 | Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma | ||
| NCT02292758 | Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | ||
| NCT00166439 | Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma | ||
| NCT02368886 | Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer | ||
| NCT05168163 | Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer | ||
| NCT04096417 | Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations | ||
| NCT02758717 | Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma | ||
| NCT02773524 | A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer | ||
| NCT05910801 | Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | ||
| NCT04879368 | RegoNivo vs Standard of Care Chemotherapy in AGOC | ||
| NCT04470544 | Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19 | ||
| NCT02297412 | Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel | ||
| NCT02873195 | Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer | ||
| NCT06160206 | Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma | ||
| NCT03765736 | Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial | ||
| NCT02585713 | Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism | ||
| NCT05246670 | PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy | ||
| NCT03043313 | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | ||
| NCT03012100 | Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer | ||
| NCT03981614 | Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer | ||
| NCT04390243 | Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation | ||
| NCT02949219 | Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | ||
| NCT03334409 | Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery | ||
| NCT03992456 | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | ||
| NCT02393690 | Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer | ||
| NCT02961790 | Oxybutynin Chloride in Managing Hot Flashes | ||
| NCT03337087 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | ||
| NCT05199285 | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab | ||
| NCT04088188 | Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma | ||
| NCT04665115 | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) | ||
| NCT04197687 | TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery | ||
| NCT03080883 | Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy | ||
| NCT05194293 | Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer | ||
| NCT02628405 | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma | ||
| NCT05356897 | Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study | ||
| NCT02973997 | Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) |
